Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Urology ; 153: 11-13, 2021 07.
Article in English | MEDLINE | ID: covidwho-1324333

ABSTRACT

OBJECTIVE: To quantify and describe urologic adverse events and symptoms after vaccination with the Pfizer-BioNTech and Moderna COVID-19 vaccines. METHODS AND MATERIALS: We queried the FDA Vaccine Adverse Event Reporting System (VAERS) for all reported symptoms following the Pfizer-BioNTech and Moderna vaccines as of February 12th, 2021. All urologic symptoms were isolated and the reported adverse events associated with each symptom were reviewed. RESULTS: Out of 15,785 adverse event reports, only 0.7% (113) described urologic symptoms. A total of 156 urologic symptoms were described amongst the 113 adverse event reports. The Pfizer-BioNTech vaccine was responsible for 61% of these reports and the Moderna vaccine was responsible for 39%. These symptoms were grouped into five different categories: Lower Urinary Tract Symptoms (n = 34, 22%), Hematuria (n = 22, 14%), Urinary Infection (n = 41, 26%), Skin and/or Soft Tissue (n = 16, 10%), and Other (n = 43, 28%). The median age of the patients reporting urologic symptoms was 63 years (IQR 44-79, Range: 19-96) and 54% of the patients were female. CONCLUSION: Urologic symptoms reported after COVID-19 vaccination are extremely rare. Given the common prevalence of many of these reported symptoms in the general population, there does not appear to be a correlation between vaccination and urologic symptoms, but as the vaccination criteria expands, further monitoring of the Vaccine Adverse Event Reporting System is needed.


Subject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Urologic Diseases/chemically induced , 2019-nCoV Vaccine mRNA-1273 , Adult , Adverse Drug Reaction Reporting Systems , Aged , Aged, 80 and over , BNT162 Vaccine , Female , Hematuria/chemically induced , Humans , Lower Urinary Tract Symptoms/chemically induced , Male , Middle Aged , SARS-CoV-2 , United States , United States Food and Drug Administration , Urinary Tract Infections/chemically induced , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL